Literature DB >> 23647279

Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells.

Christine Dufès1, Majed Al Robaian, Sukrut Somani.   

Abstract

The potential use of many promising novel drugs is limited by their inability to specifically reach their site of action after intravenous administration, without secondary effects on healthy tissues. In order to remediate this problem, the protein transferrin (Tf) has been extensively studied as a targeting molecule for the transport of drug and gene delivery systems to the brain and cancer cells. A wide range of delivery approaches have been developed to target the Tf receptor and they have already improved the specific delivery of Tf-bearing therapeutic agents to their site of action. This review provides a summary of the numerous delivery strategies used to target the Tf receptor and focuses on recent therapeutic advances.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23647279     DOI: 10.4155/tde.13.21

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  24 in total

1.  Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack.

Authors:  Marc Cinci; Srinivas Mamidi; Wenhan Li; Volker Fehring; Michael Kirschfink
Journal:  Target Oncol       Date:  2014-11-15       Impact factor: 4.493

Review 2.  Strategies to target drugs to gliomas and CNS metastases of solid tumors.

Authors:  B Milojkovic Kerklaan; O van Tellingen; A D R Huitema; J H Beijnen; W Boogerd; J H M Schellens; D Brandsma
Journal:  J Neurol       Date:  2015-10-17       Impact factor: 4.849

3.  Automated selection of regions of interest for intensity-based FRET analysis of transferrin endocytic trafficking in normal vs. cancer cells.

Authors:  Ronak Talati; Andrew Vanderpoel; Amina Eladdadi; Kate Anderson; Ken Abe; Margarida Barroso
Journal:  Methods       Date:  2013-08-28       Impact factor: 3.608

4.  Activatable Protein Nanoparticles for Targeted Delivery of Therapeutic Peptides.

Authors:  Xi Yu; Xingchun Gou; Peng Wu; Liang Han; Daofeng Tian; Fengyi Du; Zeming Chen; Fuyao Liu; Gang Deng; Ann T Chen; Chao Ma; Jun Liu; Sara M Hashmi; Xing Guo; Xiaolong Wang; Haitian Zhao; Xinran Liu; Xudong Zhu; Kevin Sheth; Qianxue Chen; Louzhen Fan; Jiangbing Zhou
Journal:  Adv Mater       Date:  2018-01-08       Impact factor: 30.849

Review 5.  Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma.

Authors:  Aniket S Wadajkar; Jimena G Dancy; David S Hersh; Pavlos Anastasiadis; Nhan L Tran; Graeme F Woodworth; Jeffrey A Winkles; Anthony J Kim
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-11-04

Review 6.  Transferrin receptor-mediated endocytosis: a useful target for cancer therapy.

Authors:  Stephanie Tortorella; Tom C Karagiannis
Journal:  J Membr Biol       Date:  2014-02-27       Impact factor: 1.843

7.  Inhibition of cerebral vascular inflammation by brain endothelium-targeted oligodeoxynucleotide complex.

Authors:  Jing Hu; Daniah Al-Waili; Aishlin Hassan; Guo-Chang Fan; Mei Xin; Jiukuan Hao
Journal:  Neuroscience       Date:  2016-04-27       Impact factor: 3.590

8.  Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.

Authors:  Sang-Soo Kim; Antonina Rait; Eric Kim; James DeMarco; Kathleen F Pirollo; Esther H Chang
Journal:  Cancer Lett       Date:  2015-09-02       Impact factor: 8.679

Review 9.  Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy - an illustration with firsthand examples.

Authors:  Rui Xue Zhang; Jason Li; Tian Zhang; Mohammad A Amini; Chunsheng He; Brian Lu; Taksim Ahmed; HoYin Lip; Andrew M Rauth; Xiao Yu Wu
Journal:  Acta Pharmacol Sin       Date:  2018-04-26       Impact factor: 6.150

10.  Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration.

Authors:  Xintao Zhang; Ting He; Zheng Chai; R Jude Samulski; Chengwen Li
Journal:  Biomaterials       Date:  2018-05-26       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.